The second antigen-binding domain binds another target, e.g., other antigen associated with cancer (CD19, CD38, HER2, EGFR, CEA, or IL-13R-a2), or a cancer-related ligand (IL-13, heregulin, VEGF). This evidence concerns the gene NRG1 and cancer.